May. 24 at 1:49 PM
$CVM That’s called biotech development across three clinical phases, where Phase III can only be completed once the required number of OS events has occurred — in this case, 296 patient deaths. If a treatment works well and keeps patients alive longer, then the study naturally takes much longer to reach those events.
This happens to many single‑asset biotechs — as long as they have only one lead product in development, everything depends on that one program. If the pivotal trial takes longer because patients live longer, the entire company timeline stretches with it.
If an SFDA approval suddenly opens a market of up to 2,000 patients under a 50/50 revenue split, you’re going to see a very clear example of what happens to a severely undervalued biotech once it enters post‑approval territory. The re‑rating effect can be dramatic — because overnight, the company shifts from speculation to commercial reality!
